Developing targeted antibodies for cancer treatment
Rationally guided discovery platform for monoclonal antibodies against carbohydrate antigens using virus-like particle conjugate immunization and high throughput selection
This study is working on a new way to create special antibodies that can better find and attack cancer cells, which could lead to more effective treatments for patients with certain types of cancer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Michigan State University NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-10885005 on NIH RePORTER |
What this research studies
This research focuses on creating a new platform to develop monoclonal antibodies that specifically target carbohydrate antigens associated with tumors. By using a unique approach that combines immunization with virus-like particles and advanced protein engineering techniques, the project aims to enhance the binding affinity and specificity of these antibodies. This could lead to better diagnostic tools and treatments for various cancers, particularly those that express tumor-associated carbohydrate antigens. Patients may benefit from more effective therapies that can precisely target cancer cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with cancers that express tumor-associated carbohydrate antigens.
Not a fit: Patients with cancers that do not express tumor-associated carbohydrate antigens may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments and improved diagnostic methods for patients with tumors expressing specific carbohydrate antigens.
How similar studies have performed: Previous research has shown promise in developing targeted therapies using monoclonal antibodies, indicating that this approach could lead to significant advancements in cancer treatment.
Where this research is happening
East Lansing, United States
- Michigan State University — East Lansing, United States (Active)
Researchers
- Principal investigator: Woldring, Daniel Ray — Michigan State University
- Study coordinator: Woldring, Daniel Ray
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.